Favipiravir‐induced nephrotoxicity in a patient with COVID‐19: A case report

Abdelbary, Asmaa; Alharafsheh, Ahmad; Ahmed, Afif; Nashwan, Abdulqadir J.

doi:10.1002/ccr3.4539

Cited by 4 publications

(2 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Administration of isoprinosine and favipiravir yielded a low (8%) survival rate outcome with a mean duration of hospitalization of 79 days. To our knowledge, no study on dose adjustment for favipiravir as an antiviral treatment for patients with both CKD and COVID-19 has been reported [ 53 ]. However, there is a similar report for oseltamivir, where its dose in patients with both CKD and a creatine clearance of less than 60 mL/min was reduced from 75 mg to only 30 mg (twice daily), while for patients with CrCL of less than 30 mL/min, the maximum dose of oseltamivir was further capped at 30 mg/day [ 52 ].…”

Section: Discussionmentioning

confidence: 99%

Factors Contributing to Chronic Kidney Disease following COVID-19 Diagnosis in Pre-Vaccinated Hospitalized Patients

et al. 2023

View full text Add to dashboard Cite

In this study, we aim to evaluate the factors that may contribute to the development of chronic kidney disease following COVID-19 infection among hospitalized patients in two private hospitals in Jakarta, Indonesia. This is a retrospective cohort study between March 2020 and September 2021. Patient selection was conducted with a convenience sampling. All patients (n = 378) meeting the inclusion criteria during the study period were enrolled. Various sociodemographic, laboratory test, and diagnostic parameters were measured before the determination of their correlation with the outcome of COVID-19 infection. In this study, all pre-vaccinated patients with COVID-19 had no history of chronic kidney disease (CKD) prior to hospital admission. From this number, approximately 75.7% of the patients developed CKD following COVID-19 diagnosis. Overall, significant correlations were established between the clinical outcome and the CKD status (p = 0.001). Interestingly, there was a significant correlation between serum creatinine level, glomerular filtration rate (GFR), and CKD (p < 0.0001). Oxygen saturation (p = 0.03), admission to the intensive care unit (ICU) (p < 0.0001), and sepsis (p = 0.005) were factors that were significantly correlated with CKD status. Additionally, the type of antibiotic agent used was significantly correlated with CKD (p = 0.011). While 82.1% of patients with CKD survived, the survival rate worsened if the patients had complications from hyperuricemia (p = 0.010). The patients who received levofloxacin and ceftriaxone had the highest (100%) survival rate after approximately 50 days of treatment. The patients who received the antiviral agent combination isoprinosine + oseltamivir + ivermectin fared better (100%) as compared to those who received isoprinosine + favipiravir (8%). Factors, such as hyperuricemia and the antibiotic agent used, contributed to CKD following COVID-19 hospitalization. Interestingly, the patients who received levofloxacin + ceftriaxone and the patients without sepsis fared the best. Overall, patients who develop CKD following COVID-19 hospitalization have a low survival rate.

show abstract

Section: Discussionmentioning

confidence: 99%

Factors Contributing to Chronic Kidney Disease following COVID-19 Diagnosis in Pre-Vaccinated Hospitalized Patients

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Mild to moderate exercise induces an increase in the excretion of urea and creatinine. It is an important consideration, particularly in medications that can induce nephrotoxicity, such as Favipiravir in COVID-19 patients ( 47 , 48 ). Also, COVID-19 patients, particularly those in intensive care units, are at the risk of developing acute kidney injury; thus, exercise should be done with caution.…”

Section: Discussionmentioning

confidence: 99%

Effects of Exercise on COVID-19 Patients: A Narrative Review

Varpaei

Khamseh

Hashemi

et al. 2022

Med. J. Islam. Republ. Iran

View full text Add to dashboard Cite

Background: Challenges concerning patient management exist worldwide, particularly in the critical care. In this review, we have summarized some studies regarding respiratory physiotherapy and exercise in COVID-19 patients. Methods: For searching related articles, PubMed, Google Scholar, Embase, and the Web of Science databases were used. Keywords such as "respiratory physiotherapy" and "COVID-19," "exercise," "effect of exercise in COVID-19," and "respiratory physiotherapy for COVID-19 in ICU" were used to identify related papers until December 2021. The abstracts and entire texts were evaluated by 3 separate reviewers. Results: During the symptomatic phase, individuals may benefit from brief durations of bed rest. Exercise appears to provide both emotional and physical benefits for individuals in the early stages of infection. As a result, it may lower viral load, minimize cytokine storm, shorten the acute phase, and expedite recovery. Mild exercise may also increase the autophagy pathway, which improves the immune system function in response to COVID-19 infection. Keeping this in mind, intense activity, especially without the guidance of an expert physical therapist, is not advantageous during the inflammatory period and may even be regarded a second hit phenomenon. Mild exercises during bed rest (e.g., acute phase) may reduce the risk of pulmonary capillary coagulation and deep vein thrombosis. Conclusion: Although respiratory physiotherapy and prone positioning in hospitalized patients, particularly in critical care, can be challenging for medical staff, they are cost-effective and noninvasive approaches for COVID-19 patients. Early physiotherapy and muscle training exercise for patients in the intensive care unit (ICU) seems to be beneficial for patients and may reduce bed rest-induced weakness, improve oxygenation, and reduce length of stay. Finally, breathing exercises can improve some symptoms of COVID-19, like dyspnea and weakness.

show abstract

Favipiravir

2022

Reactions Weekly

View full text Add to dashboard Cite

Favipiravir‐induced nephrotoxicity in a patient with COVID‐19: A case report

Cited by 4 publications

References 9 publications

Factors Contributing to Chronic Kidney Disease following COVID-19 Diagnosis in Pre-Vaccinated Hospitalized Patients

Factors Contributing to Chronic Kidney Disease following COVID-19 Diagnosis in Pre-Vaccinated Hospitalized Patients

Effects of Exercise on COVID-19 Patients: A Narrative Review

Favipiravir

Contact Info

Product

Resources

About